Convalescent Plasma News and Research

RSS

SARS-CoV-2 B.1.1.345 variant carrying E484K mutation detected in New York

The report, published in the journal Clinical Infectious Diseases, revealed that the variant detected has been spreading at an alarming rate since November. By February 2021, it accounted for 12.3 percent of all cases in the area.

8 Jun 2021

SARS-CoV-2 immunity persists for up to 11 months after natural infection

The study, published in the Journal of Infectious Diseases, determined how circulating antibody levels change after being infected with SARS-CoV-2.

8 Jun 2021

Cell-to-cell contact helps in spreading SARS-CoV-2, finds study

People aren’t the only ones who should be social distancing — new research shows our cells need to as well. Researchers from Ohio State University in Columbus, Ohio, USA, used in-culture techniques to confirm SARS-CoV-2 transmission via cell-to-cell contact.

8 Jun 2021

What is the role of monoclonal antibody therapy in treating COVID-19?

A new study has been published in the journal Vaccines that deals with the present state of research on using mAbs for the treatment of the COVID-19 disease. Many clinical trials are being conducted to evaluate the efficacy and safety of several newly designed mAbs. Some of the mAbs are directed towards immune system responses, i.e., non-SARS-CoV-2 specific mAbs, while others are devised to neutralize the SARS-CoV-2 protein structure, i.e., SARS-CoV-2 specific mAbs.

8 Jun 2021

Reduced use of convalescent plasma associated with higher COVID-19 mortality rate

A new study from researchers at Johns Hopkins Bloomberg School of Public Health and colleagues suggests a slowdown in the use of convalescent plasma to treat hospitalized COVID-19 patients led to a higher COVID-19 mortality during a critical period during this past winter's surge.

8 Jun 2021

SARS-CoV-2 evades neutralizing antibodies and rapidly spreads by cell fusion, finds study

In a new study by researchers in the UK, Germany and South Africa, this process is visualized using time-lapse microscopy of a human cell lung line, demonstrating that SARS-CoV-2 can induce cell-to-cell fusion within 6 hours post-infection. Further, the application of neutralizing monoclonal antibodies or convalescent plasma was unable to prevent the spread of the virus by this mechanism, suggesting that removing SARS-CoV-2 from cells permissive of cell membrane fusion could be more difficult than other types of cell.

4 Jun 2021

Hydroxychloroquine + Azithromycin therapy at a higher dose improved survival by nearly 200% in ventilated COVID patients

However, a fascinating new study posted to the medRxiv* preprint server suggests that such disappointment may have been both premature and unwarranted, based on a re-analysis of over 250 patients on invasive mechanical ventilation (IMV) during the first two months of the pandemic.

2 Jun 2021

Long COVID patients at higher risk of small airway disease

The preprint discussed herein describes the effects of SARS-CoV-2 on lung structure and function in patients with long COVID.

2 Jun 2021

Study links barotrauma to COVID-19 in younger patients

To better understand the possible relationship between severe infection and poor in-hospital outcomes, researchers from the Internal Medicine, and the Pulmonary Critical Care Medicine, Rutgers University, Newark, USA, presented a case series linking barotrauma to COVID-19 in younger patients.

28 May 2021

Nanobody inhalation found to be effective against COVID-19 in hamsters

In a recent paper, researchers describe an aerosolized nanobody formulation that was found to effectively block SARS-CoV-2 in Syrian hamsters.

27 May 2021

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

Researchers investigate antibodies that best neutralize SARS-CoV-2 in COVID-19 patients

The COVID-19 pandemic has now claimed over 2 million deaths worldwide, and this number is only increasing. In response, health agencies have rolled out tests to diagnose and understand the disease.

12 May 2021

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

An interesting new study describes the emergence of several such variants from a chronically immunosuppressed COVID-19 patient, who remained infected for over 170 days before clearing the virus.

7 May 2021

Large-scale study focuses on COVID-19 antibodies in asymptomatic and symptomatic patients

MUSC Hollings Cancer Center researchers added to the understanding of the protective immune response against the SARS-CoV-2 virus in a study published in April in iScience.

6 May 2021

About 84% of antibodies in plasma target non-RBD epitopes on SARS-CoV-2 spike protein, finds study

In a new study recently published in the journal Science, a team of researchers in the U.S. found that most of the antibodies circulating in the blood target areas of the viral spike protein outside the receptor-binding domain (RBD), the part of the spike that binds directly to human cell receptors.

6 May 2021

UT Southwestern reports first cases of Brazilian variant of COVID-19 infection in North Texas

UT Southwestern Medical Center scientists have identified the first cases of the Brazilian variant of COVID-19 infection in North Texas using next-generation sequencing technologies along with PCR testing.

26 Apr 2021

Real-world study in India finds COVISHIELD vaccine safe and effective

New research led by Naresh Trehan of Medanta-The Medicity in India found the COVISHIELD (ChAdOx1 nCoV-19 Corona Virus Vaccine) vaccine produced an immune response from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) two weeks after vaccination with limited side effects.

26 Apr 2021

NIH to conduct large trial for COVID-19 polyclonal antibody therapies

The National Institutes of Health (NIH) in the USA are to conduct a large-scale clinical trial to evaluate a new fully-human polyclonal antibody therapy targeted at severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

23 Apr 2021

Immune escape by SARS-CoV-2 mutations acquired in mink

A new study, published in Cell Reports, suggests that SARS-CoV-2 may have acquired such immune evasion mutations during its transmission in farmed mink.

21 Apr 2021

Chronic SARS-CoV-2 infections favor viral adaptation, says study

A new study offers a look at how to keep these hopes alive in the current context of highly infectious variants, which often display immune escape mutations.

20 Apr 2021

Convalescent Plasma News and Research

SARS-CoV-2 B.1.1.345 variant carrying E484K mutation detected in New York

SARS-CoV-2 immunity persists for up to 11 months after natural infection

Cell-to-cell contact helps in spreading SARS-CoV-2, finds study

What is the role of monoclonal antibody therapy in treating COVID-19?

Reduced use of convalescent plasma associated with higher COVID-19 mortality rate

SARS-CoV-2 evades neutralizing antibodies and rapidly spreads by cell fusion, finds study

Hydroxychloroquine + Azithromycin therapy at a higher dose improved survival by nearly 200% in ventilated COVID patients

Long COVID patients at higher risk of small airway disease

Study links barotrauma to COVID-19 in younger patients

Nanobody inhalation found to be effective against COVID-19 in hamsters

Facets of SARS-CoV-2 infection and animal models

Researchers investigate antibodies that best neutralize SARS-CoV-2 in COVID-19 patients

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

Large-scale study focuses on COVID-19 antibodies in asymptomatic and symptomatic patients

About 84% of antibodies in plasma target non-RBD epitopes on SARS-CoV-2 spike protein, finds study

UT Southwestern reports first cases of Brazilian variant of COVID-19 infection in North Texas

Real-world study in India finds COVISHIELD vaccine safe and effective

NIH to conduct large trial for COVID-19 polyclonal antibody therapies

Immune escape by SARS-CoV-2 mutations acquired in mink

Chronic SARS-CoV-2 infections favor viral adaptation, says study

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News